Detalhe da pesquisa
1.
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Cancer
; 126(10): 2146-2152, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32073648
2.
Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil.
Cancer
; 123(23): 4594-4607, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881377
3.
NCCN Guidelines Insights: Bone Cancer, Version 2.2017.
J Natl Compr Canc Netw
; 15(2): 155-167, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28188186
4.
Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life.
Cancer
; 120(24): 3994-4002, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25143048
5.
Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.
J Cancer Surviv
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630333
6.
Bone cancer.
J Natl Compr Canc Netw
; 11(6): 688-723, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23744868
7.
Risk Factors for Functional Outcomes in Advanced Laryngeal Squamous Cell Carcinoma.
Laryngoscope
; 133(3): 594-600, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35611799
8.
Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV-Related Oropharyngeal Squamous Cell Carcinoma.
Otolaryngol Head Neck Surg
; 168(5): 1089-1096, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36939390
9.
Audiologic Follow-up in Patients With Head and Neck Cancer Treated With Cisplatin and Radiation.
Laryngoscope
; 133(11): 3161-3168, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36995150
10.
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Cancer Res
; 83(19): 3252-3263, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37339176
11.
Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer.
Clin Cancer Res
; 29(20): 4196-4208, 2023 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556118
12.
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Sci Immunol
; 8(87): eadf4968, 2023 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37683037
13.
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
J Cancer Res Clin Oncol
; 149(15): 14125-14136, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552307
14.
Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
Cancer Treat Rev
; 109: 102428, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35753157
15.
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer.
Cancers (Basel)
; 14(10)2022 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35625959
16.
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
Oral Oncol
; 115: 105192, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33571736
17.
Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma.
Rare Tumors
; 13: 20363613211052498, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34646430
18.
Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
Clin Cancer Res
; 27(8): 2326-2339, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33547198
19.
Duration of radiation therapy is associated with worse survival in head and neck cancer.
Oral Oncol
; 108: 104819, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32485609
20.
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Thyroid
; 30(9): 1254-1262, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32538690